Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia

• Status: Terminated
• Trial end date: 2009-05-18
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the lon-term safety and tolerability of [S,S]-reboxetine in patients with fibromyalgia

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Reboxetine

Criteria

Inclusion Criteria:

• Diagnosis of patients meeting the ACR criteria for fibromyalgia (i.e. widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites)

Exclusion Criteria:

• Patients with other severe pain (e.g. DPN and PHN) that may confound assessment or self-evaluation of the pain associated with fibromyalgia